Lenvatinib mesylate

Cat. No.: 0225LY-0772

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, and HPLC.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Lenvatinib mesylate is an orally administered, multi-targeted inhibitor that displays strong antitumor activity by targeting KIT, RET, PDGFR, FGFR1-4, and VEGFR1-3.

Synonym: 857890-39-2; Lenvima; Lenvatinib methanesulfonate; N-(4-((6-Carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)-N'-cyclopropylurea monomethanesulfonate; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide; 6-carbamoyl-4-(3-chloro-4-((cyclopropylcarbamoyl)amino)phenoxy)-7-methoxyquinolin-1-ium methanesulfonate; 4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide monomethanesulfonate

CAS No.: 857890-39-2

Compound CID: 11237762

Formula: C₂₂H₂₃ClN₄O₇S

Formula Weight: 522.96

Specification

Targets&IC50: FGFR1: 46 nM; PDGFRβ: 39 nM; PDGFRα: 51 nM; c-Kit: 100 nM; VEGFR1: 22 nM; VEGFR2: 4 nM; VEGFR3: 5.2 nM

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Lenvatinib mesylate can be used in thyroid cancer and hepatology research to study the multi-target inhibition of VEGFR, FGFR, and PDGFR.